Madrigal Pharmaceuticals (MDGL) Shares Outstanding (Weighted Average) (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Shares Outstanding (Weighted Average) data on file, last reported at $29.0 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $29.0 million, up 3.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $29.0 million (up 3.37% YoY), and the FY2025 annual result was $28.4 million, up 5.58% from the prior year.
• Shares Outstanding (Weighted Average) advanced to $29.0 million in Q1 2026 per MDGL's latest filing, from $28.4 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $29.0 million in Q1 2026 and troughed at $17.1 million in Q1 2022.
• A 5-year average of $22.1 million and a median of $20.7 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2022 and 2025: Shares Outstanding (Weighted Average) advanced 2.79% in 2022, then surged 40.42% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $17.1 million in 2022, then increased by 25.82% to $21.6 million in 2023, then increased by 24.79% to $26.9 million in 2024, then grew by 5.58% to $28.4 million in 2025, then grew by 2.19% to $29.0 million in 2026.
• Business Quant data shows MDGL's Shares Outstanding (Weighted Average) at $29.0 million in Q1 2026, $28.4 million in Q4 2025, and $28.5 million in Q3 2025.